JP2024113040A5 - - Google Patents

Download PDF

Info

Publication number
JP2024113040A5
JP2024113040A5 JP2024090480A JP2024090480A JP2024113040A5 JP 2024113040 A5 JP2024113040 A5 JP 2024113040A5 JP 2024090480 A JP2024090480 A JP 2024090480A JP 2024090480 A JP2024090480 A JP 2024090480A JP 2024113040 A5 JP2024113040 A5 JP 2024113040A5
Authority
JP
Japan
Prior art keywords
fragment
peptide linker
region
domain
isolated heteromultimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024090480A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024113040A (ja
JP7835796B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2020/035196 external-priority patent/WO2020243477A2/en
Application filed filed Critical
Publication of JP2024113040A publication Critical patent/JP2024113040A/ja
Publication of JP2024113040A5 publication Critical patent/JP2024113040A5/ja
Application granted granted Critical
Publication of JP7835796B2 publication Critical patent/JP7835796B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024090480A 2019-05-30 2024-06-04 抗体の二量体化を促進するためのヒンジ領域の操作 Active JP7835796B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962854907P 2019-05-30 2019-05-30
US62/854,907 2019-05-30
PCT/US2020/035196 WO2020243477A2 (en) 2019-05-30 2020-05-29 Engineering the hinge region to drive antibody dimerization
JP2021570175A JP7500619B2 (ja) 2019-05-30 2020-05-29 抗体の二量体化を促進するためのヒンジ領域の操作

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021570175A Division JP7500619B2 (ja) 2019-05-30 2020-05-29 抗体の二量体化を促進するためのヒンジ領域の操作

Publications (3)

Publication Number Publication Date
JP2024113040A JP2024113040A (ja) 2024-08-21
JP2024113040A5 true JP2024113040A5 (https=) 2025-01-27
JP7835796B2 JP7835796B2 (ja) 2026-03-25

Family

ID=72234906

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021570175A Active JP7500619B2 (ja) 2019-05-30 2020-05-29 抗体の二量体化を促進するためのヒンジ領域の操作
JP2024090480A Active JP7835796B2 (ja) 2019-05-30 2024-06-04 抗体の二量体化を促進するためのヒンジ領域の操作

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021570175A Active JP7500619B2 (ja) 2019-05-30 2020-05-29 抗体の二量体化を促進するためのヒンジ領域の操作

Country Status (11)

Country Link
EP (1) EP3976643A2 (https=)
JP (2) JP7500619B2 (https=)
KR (1) KR20220016139A (https=)
CN (2) CN114174344B (https=)
AU (1) AU2020283890A1 (https=)
CA (1) CA3141690A1 (https=)
EA (1) EA202193322A1 (https=)
MX (1) MX2021014534A (https=)
SG (1) SG11202112926YA (https=)
TW (2) TW202525844A (https=)
WO (1) WO2020243477A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110669137B (zh) * 2019-10-24 2021-07-16 高新 一种多特异性抗体及其制备方法和用途
JP2024517671A (ja) * 2021-04-23 2024-04-23 チマゲン・バイオサイエンシズ,リミテッド ヘテロ二量体抗体およびその抗原結合断片
CN119604525A (zh) * 2022-07-22 2025-03-11 信达生物制药(苏州)有限公司 促进多特异性抗体的重链和轻链同源配对的突变体
CN115232214A (zh) * 2022-08-16 2022-10-25 广州市拜沃思生物科技有限公司 一种双特异性抗体及其制备方法和应用
CN121712805A (zh) * 2023-05-24 2026-03-20 三星生物株式会社 Ch3结构域变体或包含该ch3结构域变体的双特异性抗体
WO2025167974A1 (zh) * 2024-02-07 2025-08-14 上海齐鲁制药研究中心有限公司 多特异性抗体或抗原结合片段

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JPH06508035A (ja) 1991-06-14 1994-09-14 ディーエヌエックス コーポレーション トランスジェニックブタにおけるヒトヘモグロビンの生産
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
KR101516823B1 (ko) 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 안정화된 폴리펩티드 조성물
IN2009DN05758A (https=) 2007-03-12 2015-07-24 Esbatech Ag
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
US8793074B2 (en) 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
US20090074780A1 (en) 2007-06-25 2009-03-19 David Urech Methods of modifying antibodies, and modified antibodies with improved functional properties
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CN114805583A (zh) 2010-05-27 2022-07-29 根马布股份公司 针对her2的单克隆抗体
US10344050B2 (en) 2011-10-27 2019-07-09 Genmab A/S Production of heterodimeric proteins
JP2015502397A (ja) 2011-12-23 2015-01-22 ファイザー・インク 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
WO2014190441A1 (en) * 2013-05-31 2014-12-04 Zymeworks Inc. Heteromultimers with reduced or silenced effector function
TWI648401B (zh) 2013-07-31 2019-01-21 安美基公司 生長分化因子15(gdf-15)構築體
ES2936810T3 (es) 2014-05-16 2023-03-22 Pfizer Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería
WO2018030806A1 (ko) 2016-08-10 2018-02-15 아주대학교산학협력단 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물

Similar Documents

Publication Publication Date Title
JP2024113040A5 (https=)
JP2020114210A5 (https=)
JP2021515798A5 (https=)
JP2020180158A5 (https=)
JP2021522162A5 (https=)
JP2013515508A5 (https=)
JP2021533779A5 (https=)
IL276903B1 (en) Bispecific egfr/cd16 antigen-binding protein
JP2020505919A5 (https=)
JP2025160226A5 (https=)
JP2022009816A5 (https=)
JPWO2019204564A5 (https=)
US20180371088A1 (en) TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT AND USES THEREOF IN CANCER THERAPY
JPWO2019175368A5 (https=)
JPWO2022094299A5 (https=)
JPWO2020037150A5 (https=)
JPWO2022042488A5 (https=)
JPWO2022111425A5 (https=)
JP7826320B2 (ja) 二重または多重特異性抗体{Bi or Multi-Specific Antibody}
JPWO2020073131A5 (https=)
WO2024061224A1 (zh) 抗her2抗体及其用途
JPWO2023056252A5 (https=)
IL321639A (en) Anti pd 1×4 1bb binding proteins
JP2021526833A5 (https=)
JPWO2021207072A5 (https=)